|
Re: 2% market penetration
|
8
|
Resverlogix Corp.
|
Nov 17, 2017 05:00PM
|
|
Re: HL
|
7
|
Resverlogix Corp.
|
Nov 17, 2017 03:55PM
|
|
Re: HL
|
5
|
Resverlogix Corp.
|
Nov 17, 2017 03:34PM
|
|
Re: BioSpace-Amgen's Repatha
|
3
|
Resverlogix Corp.
|
Nov 16, 2017 09:57AM
|
|
Re: Beating the dead horse
|
7
|
Resverlogix Corp.
|
Nov 12, 2017 01:49PM
|
|
Re: RVX announces first right of refusal for license deal in the US
|
10
|
Resverlogix Corp.
|
Oct 24, 2017 05:05PM
|
|
New article on Apabetalone
|
6
|
Resverlogix Corp.
|
Oct 16, 2017 10:30AM
|
|
All - I mean ALL - about the ASSURE trial
|
5
|
Resverlogix Corp.
|
Sep 15, 2017 03:19PM
|
|
Re: Courtesy
|
4
|
Resverlogix Corp.
|
Aug 22, 2017 04:31PM
|
|
Did you know...?
|
10
|
Resverlogix Corp.
|
Jul 05, 2017 04:33PM
|
|
Re: Novartis Phase III study shows Canakinumab reduces MACE events
|
6
|
Resverlogix Corp.
|
Jun 22, 2017 02:12PM
|
|
Resverlax
|
15
|
Resverlogix Corp.
|
Jun 12, 2017 06:27PM
|
|
Re: Friedreich’s Ataxia Therapy News - Very interesting
|
2
|
Resverlogix Corp.
|
May 26, 2017 04:27PM
|
|
Re: Friedreich’s Ataxia Therapy News - Very interesting
|
3
|
Resverlogix Corp.
|
May 26, 2017 04:01PM
|
|
Re: Friedreich’s Ataxia Therapy News - Very interesting
|
6
|
Resverlogix Corp.
|
May 26, 2017 09:18AM
|
|
Re: Friedreich’s Ataxia Therapy News - Very interesting
|
6
|
Resverlogix Corp.
|
May 26, 2017 08:37AM
|
|
Re: New patent application - USA Inventor
|
3
|
Resverlogix Corp.
|
May 10, 2017 02:08PM
|
|
Re: New patent application - USA Inventor
|
4
|
Resverlogix Corp.
|
May 08, 2017 03:51PM
|
|
Re: New patent application (filed January 18, 2017; published May 4, 2017)
|
2
|
Resverlogix Corp.
|
May 08, 2017 12:07PM
|
|
New patent application (filed January 18, 2017; published May 4, 2017)
|
7
|
Resverlogix Corp.
|
May 08, 2017 11:32AM
|
